Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 225 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Deep Vein Thrombosis Clear all

Conditions: Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism
Interventions: Standard heparin dose, Real time heparin dose adjustment; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Deep Venous Thrombosis, Pulmonary Embolism
Interventions: Enoxaparin, Fondaparinux; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Other Acute Illnesses Presenting to the Hospital, Heart Failure, Pneumonia, Deep Venous Thrombosis, Cellulitis, Abdominal Aortic Aneurysm, Acute Cholecystitis, Peritoneal Free Fluid, Hydronephrosis, Pleural Effusion, Urinary Retention
Interventions: Not listed
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Pancreatic Cancer, Venous Thromboembolism
Interventions: Dalteparin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Deep Vein Thrombosis (DVT), Thrombus in the Peripheral Venous Vasculature, Venous Embolism, Thrombus in the Central and Peripheral Circulatory System, Including Saphenous Vein Grafts
Interventions: Aspiration thrombectomy system; Device
Lead sponsor: Argon Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Fort Lauderdale, Florida • Indianapolis, Indiana • Edgewood, Kentucky + 1 more

Conditions: Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism, Trauma
Interventions: The Angel® Catheter; Device
Lead sponsor: BiO2 Medical; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 21
States / cities: Los Angeles, California • San Diego, California • Loveland, Colorado + 18 more

Conditions: Heart Attack, Cardiac Arrest, Congestive Heart Failure, Atrial Fibrillation, Angina, Deep Vein Thrombosis, Pulmonary Embolism, Respiratory Arrest, Respiratory Failure, Pneumonia, Gastrointestinal Bleed, Stomach Ulcer, Delirium, Stroke, Nerve Injury, Surgical Wound Infection
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 73,952 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Deep Vein Thrombosis
Interventions: SanOrg34006, LMW heparin, Unfractionated heparin, Vitamin K antagonist (VKA); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 1,452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 24
States / cities: Denver, Colorado • Jacksonville, Florida • Melbourne, Florida + 21 more

Conditions: Heart Failure, Cardiomyopathies, Pulmonary Hypertension, Myocarditis; Acute or Subacute, Myocarditis Due to Drug, Myocarditis Viral, Pericardial Diseases, Valvular Heart Diseases, Hypertension, Sepsis, Acute Kidney Injury, Pulmonary Edema - Acute, Pulmonary Edema With Heart Failure, Pulmonary Edemas, Acute Respiratory Distress Syndrome, Pulmonary Embolism Acute, Pulmonary Embolism (Diagnosis), Pulmonary Embolism Acute Massive, Pulmonary Embolism Subacute Massive, Venous Thrombosis Pulmonary, Venous Thrombosis (Disorder), Venous Thrombosis, Deep, Peripheral Arterial Disease, Peripheral Arterial Disease (PAD), Aortic Diseases, Muskuloskeletal Diseases, Brain Aging, Brain Aneurysm, Brain Aging Related Conditions, Ultrasound, Ultrasound Exams, Ultrasound Guidance
Interventions: OMNIPHYS Multimodal Ultrasound Imaging System; Device
Lead sponsor: Truway Health, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2046
U.S. locations: 1
States / cities: New York, New York

Conditions: Deep Vein Thrombosis, Pulmonary Embolism
Interventions: Discontinue anticoagulant therapy (Negative d-dimer), Continue on anticoagulant therapy (positive d-dimer); Other
Lead sponsor: McMaster University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Iowa City, Iowa • Boston, Massachusetts + 3 more

Conditions: Deep Venous Thrombosis, Post Thrombotic Syndrome
Interventions: Catheter directed thrombolysis plus anticoagulation, Anticoagulation; Combination Product · Drug
Lead sponsor: University of Toledo Health Science Campus; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Venous Thromboembolic Disease, Deep Vein Thrombosis, Pulmonary Embolism
Interventions: 5000 Units unfractionated Heparin Q 8 hr, 30mg enoxaparin Q12 hr; Drug
Lead sponsor: Scripps Health; Other
Eligibility: 18 Years and older
Enrollment: 495 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: San Diego, California

Conditions: Deep Vein Thrombosis, Venous Thrombosis
Interventions: edoxaban tosylate, enoxaparin/unfractionated heparin, warfarin; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 29
States / cities: Dothan, Alabama • Montgomery, Alabama • Sacramento, California + 26 more

Conditions: Varicose Veins
Interventions: Not listed
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Spine Metastasis
Interventions: Apixaban; Drug
Lead sponsor: James Bayley; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Pittburgh, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Venous Thrombosis, Pulmonary Embolism
Interventions: Apixaban, Enoxaparin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 40 Years and older
Enrollment: 6,758 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 48
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 42 more

Conditions: Critical Illness, Deep Venous Thrombosis
Interventions: LMWH (Fragmin, dalteparin), Unfractionated Heparin; Drug
Lead sponsor: McMaster University; Other
Eligibility: 18 Years and older
Enrollment: 3,659 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 4
States / cities: Rochester, Minnesota • St Louis, Missouri • Providence, Rhode Island + 1 more

Conditions: Deep Vein Thrombosis, DVT
Interventions: Indigo Aspiration System; Device
Lead sponsor: Penumbra Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 42
States / cities: La Mesa, California • Long Beach, California • Los Angeles, California + 32 more

Conditions: Venous Thrombosis
Interventions: Arixtra (fondaparinux sodium), Intermittent compression devices (ICD); Drug · Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 85 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Pulmonary Embolism, Thromboembolism, Thrombosis, Venous Thrombosis, Venous Thromboembolism
Interventions: BAY 59-7939, ASA; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 3,365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 24
States / cities: Beverly Hills, California • La Jolla, California • Ventura, California + 19 more

Conditions: Venous Thromboembolism, Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma
Interventions: Kinisoquin™, Placebo; Drug
Lead sponsor: Quercis Pharma AG; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Ventura, California • Miami Lakes, Florida • Boston, Massachusetts

Conditions: Coronary Artery Bypass Grafting, Postoperative Atrial Fibrilation, Stroke, Systemic Embolism, Deep Venous Thrombosis
Interventions: Apixaban, Warfarin; Drug
Lead sponsor: Sanford Health; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Deep Vein Thrombosis of Lower Limb, Pulmonary Embolism (PE), Bleeding
Interventions: ActiveCare CECT device, Enoxaparin; Device · Drug
Lead sponsor: Medical Compression Systems; Industry
Eligibility: 18 Years and older
Enrollment: 411 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 9
States / cities: La Jolla, California • Loma Linda, California • Los Angeles, California + 6 more

Conditions: Catheter Infection, Catheter Thrombosis, Catheter Complications
Interventions: Angiodynamics BioFlo Midline Catheter, Teleflex Arrowg+ard Blue Advanced Midline Catheter; Device
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Royal Oak, Michigan

Search by objective public record fields.

Evaluation of Anti-Xa Levels in Surgery Patients Receiving Weight-based Heparin

Comparing Enoxaparin to Fondaparinux to Prevent Venous Thromboembolism (VTE) in Bariatric Surgical Patients

Evaluation of Implementation of a National Point-of-Care Ultrasound Training Program

Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients

Cleaner Long-tErm Assessment Registry - Venous Insights and Efficacy With eXtended Tracking

The Angel® Catheter Pivotal Clinical Trial

Systematic Assessment and Targeted Improvement of Services Following Yearlong Surgical Outcomes Surveys

Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)

Multimodal Physiologic State Intelligence Study

D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months

Catheter-directed Thrombolysis Compared to Anticoagulation Alone for Acute Primary Iliofemoral Deep Venous Thrombosis

Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin

A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis

Evaluation of Endovenous Sclerotherapy for Treatment of Varicose Veins

Extended Prophylactic Anticoagulation Following Spinal Surgery for Metastatic Disease

Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness

PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)

BOLT-DVT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis

Study of Arixtra (Fondaparinux Sodium) to Prevent Blood Clots in Women Undergoing Abdominopelvic Surgery for Likely Gynecologic Malignancy

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer

Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation

Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)

Midlines and Thrombophlebitis